EUCTR2009-012569-79-FR进行中（未招募）1 期
An open-label, non-randomized study to evaluate the efficacy and safety of BAY 94-9172 (ZK 6013443) positron emission tomography (PET) imaging for detection/exclusion of cerebral ß-amyloid when compared to postmortem histopathology - Safety and efficacy of positron emission tomography imaging with BAY 94-9172 (ZK 6013443)
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 218
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Subjects with a low probability of cerebral ß-amyloid deposition, e.g. non-demented volunteers and subjects with a high probability of ß-amyloid deposition, e.g.patients diagnosed with AD or Dementia with Lewy Bodies (DLB), 10 cognitively normal and young healthy volunteers between 21 and 40 years of age.
- •Each study participant has to meet the following criteria:
- •- is at least 21 years of age
- •- females, no child-bearing potential of negative urine pregnancy test on day of BAY 94-9172 injection
- •- exhibits visual, auditory, and communicative capabilities adequate to provide informed consent or assent and comply with study procedures
- •- is willing and able to lie down in MRI and PET scanners
- •- is willing to donate their brain for postmortem examination in case of death (not required of the healthy volunteers)
- •- the subject or the subject and/or legally acceptable representative will be compliant and have a high probability of completing the study in the opinion of the investigator
- •- has been fully informed about the study, including provisions of the Health Insurance Portability and Accountability, as applicable, and informed consent or assent has been signed and dated by the subject and/or the subject's legally acceptable representative
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Each subject who meets any of the following criteria must not participate in this study:
- •- has signs of major cerebrovascular disease as verified by medical history, e.g. fulfills the operational definitions of imaging guidelines of the NINDS-AIREN criteria for vascular dementia and by magnetic resonance brain imaging, e.g. an ARWMC score of > 2
- •- has any contraindication to magnetic resonance imaging examination, e.g. metal implants or phobia as determined by the onsite radiologist performing the scan
- •- is scheduled for surgery and/or another invasive procedure within the time period of up to 7 days following study drug administration
- •- is allergic to the study drug or any of its constituents
- •- has received any contrast material (X-ray, MRI) or radiopharmaceutical within 48 hours prior to or a therapeutic radiopharmaceutical (e.g. 131I) within 10 days prior to the administration of the study drug or for whom administration of such substances is planned within 7 days following study drug administration
- •- has been previously enrolled in this study or participated in a clinical study involving an investigational pharmaceutical product within 30 days prior to screening and/or was administered a radiopharmaceutical within 10 radioactive half-lives to study drug administration in this study
- •- is medically unstable and whose clinical course during the observation period is unpredicatable as determined by the onsite investigator, e.g. patients/volunteers with acute myocardial infarction, stroke or renal failure.
研究者
相似试验
进行中（未招募）
1 期
Safety and efficacy of PET imaging with BAY 94-9172 (ZK 6013443)EUCTR2009-012569-79-DEBayer AG250
尚未招募
不适用
An Open Label, Non-randomised study to evaluate the safety, efficacy, tolerability and compliance of the Tongue Tamer Mandibular Advancement Splint in patients with Obstructive Sleep ApnoeaObstructive Sleep ApnoeaRespiratory - Sleep apnoeaACTRN12615000037505Prof. Peter Cistulli15
进行中（未招募）
1 期
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)Metachromatic Leukodystrophy (MLD) is an autosomal recessive disorder caused by mutationsMedDRA version: 20.0Level: PTClassification code: 10067609Term: Metachromatic leukodystrophy Class: 100000004850CTIS2024-511971-13-00Orchard Therapeutics (Europe) Limited6
进行中（未招募）
1 期
A clinical trial to evaluate the effect of OTL-200, a gene therapy treatment in patients with Late Juvenile (LJ) Metachromatic Leukodystrophy (MLD)EUCTR2019-002636-82-ITOrchard Therapeutics (Europe) Limited6
进行中（未招募）
3 期
An Open-Label, Non-Randomized Study to Assess the Safety and Efficacy of Leniolisib in Japanese Patients With Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Followed By an Open-Label Long-Term ExtensioJPRN-jRCT2061230036Bradt Jason3